Nisa Investment Advisors LLC grew its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 23.1% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,317 shares of the biotechnology company’s stock after acquiring an additional 247 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Sarepta Therapeutics were worth $160,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently modified their holdings of the business. MassMutual Private Wealth & Trust FSB raised its stake in Sarepta Therapeutics by 169.6% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 156 shares in the last quarter. Sunbelt Securities Inc. increased its holdings in shares of Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after buying an additional 232 shares during the last quarter. Huntington National Bank raised its position in shares of Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 175 shares in the last quarter. UMB Bank n.a. lifted its holdings in shares of Sarepta Therapeutics by 105.9% in the 3rd quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 197 shares during the last quarter. Finally, Values First Advisors Inc. purchased a new position in Sarepta Therapeutics in the third quarter worth about $59,000. 86.68% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of equities research analysts have issued reports on the company. Jefferies Financial Group began coverage on Sarepta Therapeutics in a research report on Monday, October 21st. They set a “buy” rating and a $165.00 price objective on the stock. Evercore ISI decreased their price target on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. StockNews.com lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Cantor Fitzgerald raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and increased their target price for the company from $152.00 to $167.00 in a research note on Thursday, November 7th. Finally, Guggenheim lifted their price target on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Sarepta Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $178.71.
Insider Buying and Selling at Sarepta Therapeutics
In related news, Director Kathryn Jean Boor sold 1,636 shares of the firm’s stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the sale, the director now owns 5,880 shares of the company’s stock, valued at $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the transaction, the director now directly owns 22,840 shares in the company, valued at $2,851,345.60. This represents a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.
Sarepta Therapeutics Stock Performance
Shares of Sarepta Therapeutics stock opened at $114.45 on Friday. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The stock’s fifty day moving average price is $122.81 and its 200-day moving average price is $127.50. The firm has a market cap of $10.93 billion, a P/E ratio of 91.56 and a beta of 0.77. Sarepta Therapeutics, Inc. has a 12 month low of $102.15 and a 12 month high of $173.25.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
Further Reading
- Five stocks we like better than Sarepta Therapeutics
- Options Trading – Understanding Strike Price
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Insider Trading – What You Need to Know
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.